Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071395
Filing Date
2025-05-14
Accepted
2025-05-14 16:12:41
Documents
47
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tennx-20250331.htm   iXBRL 10-Q 1062715
2 EX-31.1 tennx-ex31_1.htm EX-31.1 16458
3 EX-31.2 tennx-ex31_2.htm EX-31.2 16909
4 EX-32.1 tennx-ex32_1.htm EX-32.1 9681
5 EX-32.2 tennx-ex32_2.htm EX-32.2 10025
  Complete submission text file 0000950170-25-071395.txt   4562354

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20250331.xsd EX-101.SCH 792399
50 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20250331_htm.xml XML 618734
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 25945634
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)